Skip to content

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study

Safety, Tolerability, and Efficacy of Enteral Nutrition Versus Standard of Care Nutrition in Hematopoietic Stem Cell Transplant Patients: A Pilot Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06004063
Enrollment
40
Registered
2023-08-22
Start date
2023-08-04
Completion date
2029-12-31
Last updated
2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stem Cell

Brief summary

The goal of this research study is to learn if feeding someone after a stem cell transplant is safe and practical.

Detailed description

Primary Objective: a. To determine the feasibility, acceptability, and safety of NG tube feeding compared with patients not electing NG tube feeding. Secondary Objectives: 1. Determine the differential effects of enteral feeding versus Parenteral feeding on nutrition, and quality of life. 2. Determine the differential effects of enteral feeding versus parenteral feeding on survival and, medical comorbidities 3. Determine the differential effects of enteral feeding versus parenteral feeding on Fitbit data study for patients co-enrolled in Pediatric Energy Balance Data Repository Protocol PA18-0130. 4. Identify differential effects on microbiome for patients co-enrolled on MDACC protocol 2014-0938 "Longitudinal Biospecimen Acquisition for All Tumor Types And At-Risk Tissue 5. Determine adverse effects of enteral feeding in this population

Interventions

DIETARY_SUPPLEMENTEnteral nutrition (EN)

Given by Nasogastric Tube

OTHERStandard care parenteral nutrition (PN)

Given by PO or Given by IV (vein)

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Have plans to be admitted or be admitted to an inpatient pediatric or adult ward for the purpose of HSCT. 2. Be greater than 2 years of age and less than 25 years of age at time of study enrollment. 3. Participants \> 18 or guardians for participants \< 18 are willing and able to give written informed consent and to comply with all of the study activities. Assent is required for children \> 7 years old. a) Participants must be English, Italian, Chinese/Mandarin, or Spanish speaking 4. Participants will be encouraged to co-enroll on two additional related energy -balance protocols (highly encouraged but not required) 1. MDACC protocol PA18-0130. This protocol will enable us to track physical activity through their receipt of a Fitbit (Pediatric Energy Balance Data Repository Protocol.) , and 2. MDACC protocol LAB99-062 "A Study to Collect Peripheral Blood, Tissue, and Bone Marrow samples from Donors and Recipients of blood and marrow transplants for Laboratory Research" which will allow collection of stool for exploration of the effects of feeding on microbiome data specifically. 5. Participants will be asked to consider co-enrollment on Stem Cell Registry study (not required): 1. PA19-0756: This is a prospective multi-center study to understand the contribution of vascular endothelial dysfunction towards morbidity and mortality among children and adolescents/young adults (AYA) undergoing HCT/CT.

Exclusion criteria

1. Patients in whom EN is contraindicated (e.g intestinal ischemia, complete bowel obstruction, or other anatomical obstructive process), or all available routes of EN are contraindicated. Surgical GT placements for the sole purpose of study participation will not be entertained. See Table 1 2. Females who are pregnant. We follow FACT guidelines. Per Foundation for the Accreditation of Cellular Therapy (FACT), female patients must have a negative pregnancy test 7 days prior to bone marrow transplant.

Design outcomes

Primary

MeasureTime frame
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0through study completion; an average of 1 year.

Countries

United States

Contacts

CONTACTShehla Razvi, MD
srazvi@mdanderson.org(713) 792-6635
CONTACTKaren Moody, MD
kmoody@mdanderson.org713-792-6610
PRINCIPAL_INVESTIGATORShehla Razvi, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026